NASDAQ · OVID
Healthcare · Biotechnology
$2.80
Up+$0.06 (+2.19%)
Updated Aug 22, 2026, 2:42 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
OVID closed at $2.80 after 21 trading sessions, up 20.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.76 | $2.83 | $2.71 | $2.80 | 1.33M |
| Aug 20, 2026 | $2.88 | $2.93 | $2.72 | $2.74 | 1.15M |
| Aug 19, 2026 | $2.90 | $2.95 | $2.84 | $2.93 | 2.88M |
| Aug 18, 2026 | $2.87 | $2.905 | $2.795 | $2.84 | 1.94M |
| Aug 17, 2026 | $2.83 | $2.92 | $2.80 | $2.89 | 1.75M |
| Aug 14, 2026 | $2.80 | $2.87 | $2.745 | $2.83 | 1.24M |
| Aug 13, 2026 | $2.65 | $2.875 | $2.62 | $2.80 | 2.24M |
| Aug 12, 2026 | $2.44 | $2.645 | $2.43 | $2.62 | 931.47K |
| Aug 11, 2026 | $2.62 | $2.65 | $2.525 | $2.58 | 903.2K |
| Aug 10, 2026 | $2.59 | $2.62 | $2.53 | $2.62 | 1.25M |
| Aug 7, 2026 | $2.69 | $2.69 | $2.60 | $2.63 | 919.7K |
| Aug 6, 2026 | $2.62 | $2.685 | $2.585 | $2.65 | 1.29M |
| Aug 5, 2026 | $2.52 | $2.68 | $2.49 | $2.62 | 2.25M |
| Aug 4, 2026 | $2.33 | $2.555 | $2.33 | $2.54 | 1.67M |
| Aug 3, 2026 | $2.222 | $2.36 | $2.222 | $2.33 | 1.68M |
| Jul 31, 2026 | $2.36 | $2.36 | $2.20 | $2.22 | 1.75M |
| Jul 30, 2026 | $2.30 | $2.375 | $2.275 | $2.37 | 1.29M |
| Jul 29, 2026 | $2.35 | $2.40 | $2.255 | $2.29 | 648.34K |
| Jul 28, 2026 | $2.42 | $2.42 | $2.24 | $2.36 | 1.35M |
| Jul 27, 2026 | $2.35 | $2.485 | $2.31 | $2.35 | 1.05M |
| Jul 24, 2026 | $2.40 | $2.40 | $2.31 | $2.33 | 984.98K |
The latest Smart Investors Daily articles mentioning OVID.
OVID research
Company profile and research snapshot.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | Oppenheimer | Outperform | — |
| Apr 15, 2026 | Wedbush | Outperform | — |
| Apr 9, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 26, 2026 | BTIG | Buy | — |
| Mar 20, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · Aug 13, 2026
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Aug 13, 2026
First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA newly-formed portfolio company with funds advised by Perceptive Advisors acquired global rights to soticlestat; Ovid secured equity in the company and the potential to receive regulatory and sales milestone payments and royalties upon successStrengthened executive leadership team with appointment of Kev
Benzinga · Aug 13, 2026
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share
Yahoo · Aug 6, 2026
Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OVID.
